Skip to main content
SpringerLink
Log in

Pharmacotherapy of Attention Deficit Hyperactivity Disorder in Adults

  • Disease Management
  • Published:
CNS Drugs Aims and scope Submit manuscript

Summary

Attention deficit hyperactivity disorder (ADHD) in adults is an increasingly recognised condition that is associated with substantial functional impairment. Adults with ADHD present with a developmental derivation of symptoms reminiscent of those in juveniles, most notably inattention and distractibility and, less commonly, hyperactivity and impulsivity. Psychiatric comorbidity with mood, anxiety, substance use and antisocial personality disorders are often found in adults with ADHD. As with children with ADHD, the mainstay of treatment in adults with the disorder is pharmacotherapy.

In contrast to the vast amount of data available on the treatment of children with ADHD, there have been only a limited number of medication studies in adults with the disorder. Nine studies (n = 245) of psychostimulants and 16 studies (n = 273) of nonstimulant medications, including antidepressants, antihypertensives and amino acids, have been published. A review of the literature indicates that the majority of controlled investigations assessed the effects of psychostimulants, while nonstimulant agents have generally been studied under open conditions.

Stimulant medications tend to result in a dose-related improvement in ADHD symptoms. The limited data suggest that standard dosages of antidepressants are effective. Agents with catecholaminergic activity have efficacy in ADHD, whereas those with predominately serotonergic properties appear not to be effective. The majority of studies suggest that stimulants are the most effective available agents for adults with ADHD, and these drugs remain the treatment of choice.

In cases of psychiatric comorbidity, residual symptoms or adverse effects, limited data suggest benefit from combining medications. Cognitive-based psychotherapy used in association with medications may play a role in treating dynamic issues, residual symptomatology and comorbid psychopathology. Future controlled studies applying stringent diagnostic criteria and outcome methodology are necessary to define further the range of pharmacotherapeutic options for adults with ADHD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bauermeister JJ, Canino G, Bird H. Epidemiology of disruptive behavior disorders. In: Greenhill L, editor. Child and adolescent psychiatric clinics of North America. Philadelphia: WB Saunders Company, 1994: 177–94

    Google Scholar 

  2. Murphy K, Barkley R. Prevalence of DSM-IV symptoms of ADHD in adult licensed drivers: implications for clinical diagnosis. J Attention Disord 1996; 1: 147–61

    Article  Google Scholar 

  3. Faraone SV, Biederman J, Chen WJ, et al. Segregation analysis of attention deficit hyperactivity disorder. Psychiatr Genet 1992; 2: 257–75

    Article  Google Scholar 

  4. Weiss G, Hechtman LT. Hyperactive children grown up. New York: The Guilford Press, 1986

    Google Scholar 

  5. Mannuzza S, Klein RG, Bonagura N, et al. Hyperactive boys almost grown up. V. Replication of psychiatric status. Arch Gen Psychiatry 1991; 48: 77–83

    Article  PubMed  CAS  Google Scholar 

  6. Manuzza S, Klein RG, Bessler A, et al. Adult outcome of hyperactive boys: educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry 1993; 50: 565–76

    Article  Google Scholar 

  7. Biederman J, Faraone SV, Spencer T, et al. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1993; 150: 1792–8

    PubMed  CAS  Google Scholar 

  8. Biederman J, Wilens TE, Mick E, et al. Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatry 1995; 152: 1652–8

    PubMed  CAS  Google Scholar 

  9. Spencer T, Biederman J, Wilens TE, et al. Is attention deficit hyperactivity disorder in adults a valid diagnosis? Harv Rev Psychiatry 1994; 1: 326–35

    Article  PubMed  CAS  Google Scholar 

  10. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Association Press, 1994

    Google Scholar 

  11. Brown T. Brown Attention Deficit Disorder Scales. San Antonio: The Psychological Corporation, 1995

    Google Scholar 

  12. Ward MF, Wender PH, Reimherr FW. The Wender Utah rating scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. Am J Psychiatry 1993; 150: 885–90

    PubMed  CAS  Google Scholar 

  13. Millstein R, Wilens T, Biederman J, et al. Presenting symptoms in ADHD in clinically referred adults with ADHD. J Attent Dis. In press

  14. Ratey JJ, Greenberg MS, Bemporad JR, et al. Unrecognized attention-deficit hyperactivity disorder in adults presenting for outpatient psychotherapy. J Child Adolesc Psychopharmacol 1992; 2: 267–75

    Article  PubMed  CAS  Google Scholar 

  15. McDermott SP, Wilens TE. Cognitive and emotional impediments to treating the adult with ADHD: a cognitive therapy perspective. In: Brown T, editor. Subtypes of attention deficit disorders in children, adolescents, and adults. Washington, DC: American Psychiatric Press, Inc. In press

  16. Spencer T, Biederman J, Wilens T, et al. Pharmacotherapy of attention deficit disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 1996; 35: 409–32

    Article  PubMed  CAS  Google Scholar 

  17. Wood DR, Reimherr FW, Wender PH, et al. Diagnosis and treatment of minimal brain dysfunction in adults. Arch Gen Psychiatry 1976; 33: 1453–60

    Article  PubMed  CAS  Google Scholar 

  18. Wender PH, Reimherr FW, Wood DR. Attention deficit disorder (‘minimal brain dysfunction’) in adults: a replication study of diagnosis and drug treatment. Arch Gen Psychiatry 1981; 38: 449–56

    Article  PubMed  CAS  Google Scholar 

  19. Wender PH, Reimherr FW, Wood D, et al. A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults. Am J Psychiatry 1985; 142: 547–52

    PubMed  CAS  Google Scholar 

  20. Gualtieri CT, Ondrusek MG, Finley C. Attention deficit disorder in adults. Clin Neuropharmacol 1985; 8: 343–56

    Article  PubMed  CAS  Google Scholar 

  21. Mattes JA, Boswell L, Oliver H. Methylphenidate effects on symptoms of attention deficit disorder in adults. Arch Gen Psychiatry 1984; 41: 1059–63

    Article  PubMed  CAS  Google Scholar 

  22. Shekim WO, Asarnow RF, Hess E, et al. A clinical and demographic profile of a sample of adults with attention deficit hyperactivity disorder, residual state. Compr Psychiatry 1990; 31: 416–25

    Article  PubMed  CAS  Google Scholar 

  23. Spencer T, Wilens TE, Biederman J, et al. A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood onset attention deficit hyperactivity disorder. Arch Gen Psychiatry 1995; 52: 434–43

    Article  PubMed  CAS  Google Scholar 

  24. Iaboni F, Bouffard R, Minde K, et al. The efficacy of methylphenidate in treating adults with attention deficit/hyperactivity disorder [abstract]. Proceedings of the American Academy of Child and Adolescent Psychiatry: 1996 Oct; Philadelphia

  25. Wilens T, Frazier JJP, Spencer T, et al. A double-blind comparison of pemoline in adults with ADHD: preliminary results [abstract]. Proceedings of the American Academy of Child and Adolescent Psychiatry: 1996 Oct; Philadelphia

  26. Wilens TE, Biederman J. The stimulants. In: Shafer D, editor. The psychiatric clinics of North America. Philadelphia: WB Saunders, 1992: 191–222

    Google Scholar 

  27. Wender P, Reimherr F, Czaijkowski L, et al. A longterm trial of methylphenidate in the treatment of ADHD adults: a placebo-controlled trial and six-month follow-up [abstract]. American College of Neuropharmacology: 1995 Dec; Puerto Rico

  28. Gualtieri CT, Hicks RE, Patrick K, et al. Clinical correlates of methylphenidate blood levels. Ther Drug Monit 1984; 6: 379–92

    Article  PubMed  CAS  Google Scholar 

  29. Langer DH, Sweeney KP, Bartenbach DE, et al. Evidence of lack of abuse or dependence following pemoline treatment: results of a retrospective survey. Drug Alcohol Depend 1986; 17: 213–27

    Article  PubMed  CAS  Google Scholar 

  30. Taylor E, Schachar R, Thorley G, et al. Which boys respond to stimulant medication? A controlled trial of methylphenidate in boys with disruptive behaviour. Psychol Med 1987; 17: 121–43

    Article  PubMed  CAS  Google Scholar 

  31. Wilens TE, Biederman J, Mick E, et al. A systematic assessment of tricyclic antidepressants in the treatment of adult attention deficit hyperactivity disorder. J Nerv Ment Dis 1995; 184: 48–50

    Google Scholar 

  32. Wilens T, Biderman J, Prince J, et al. A double-blind, placebo-controlled trial of desipramine for adults with ADHD. Am J Psychiatry 1996; 153: 1147–53

    PubMed  CAS  Google Scholar 

  33. Wender PH, Reimherr FW. Bupropion treatment of attention deficit hyperactivity disorder in adults. Am J Psychiatry 1990; 147: 1018–20

    PubMed  CAS  Google Scholar 

  34. Wender PH, Wood DR, Reimherr FW, et al. An open trial of pargyline in the treatment of attention deficit disorder, residual type. Psychiatry Res 1983; 9: 329–36

    Article  PubMed  CAS  Google Scholar 

  35. Wender PH, Wood DR, Reimherr FW. Pharmacological treatment of attention deficit disorder residual type (ADD.RT, ‘minimal brain dysfunction’, ‘hyperactivity’) in adults. Psychopharmacol Bull 1985; 21: 222–30

    PubMed  CAS  Google Scholar 

  36. Ernst M, Liebenauer L, Jons P, et al. Selegiline in adults with attention deficit hyperactivity disorder: clinical efficacy and safety. Psychopharmacol Bull 1996; 32: 327–34

    PubMed  CAS  Google Scholar 

  37. Spencer T, Biedennan J, Wilens T, et al. Tolerability and efficacy of tomoxetine for adults with attention deficit hyperactivity disorder. Am J Psychiatry. In press

  38. Shekim WO, Masterson A, Cantwell DP, et al. Nomifensine maleate in adult attention deficit disorder. J Nerv Ment Dis 1989; 177: 296–9

    Article  PubMed  CAS  Google Scholar 

  39. Shekim WO, Antun F, Hanna GL, et al. S-adenosyl-1-methionine (SAM) in adults with ADHD, RS: preliminary results from an open trial. Psychopharmacol Bull 1990; 26: 249–53

    PubMed  CAS  Google Scholar 

  40. Adler LA, Resnick S, Kunz M, et al. Open label trial of venlafaxine in adults with attention deficit disorder. Psychopharmacol Bull 1995; 31: 785–8

    PubMed  CAS  Google Scholar 

  41. Findling RL, Schwartz MA, Flannery DJ, et al. Venlafaxine in adults with attention deficit/hyperactivity disorder: an open clinical trial. J Clin Psychiatry 1996; 57: 184–9

    PubMed  CAS  Google Scholar 

  42. Reimherr FW, Hedges DW, Strong RE, et al. An open trial of venlafaxine in adult patients with attention deficit hyperactivity disorder [abstract]. New Clinical Drug Evaluation Unit program 35th Annual Meeting: 1995 May; Orlando

  43. Mattes JA. Propranolol for adults with temper outbursts and residual attention deficit disorder. J Clin Psychopharmacol 1986; 6: 299–302

    Article  PubMed  CAS  Google Scholar 

  44. Reimherr FW, Wender PH, Wood DR, et al. An open trial of L-tyrosine in the treatment of attention deficit hyperactivity disorder, residual type. Am J Psychiatry 1987; 144: 1071–3

    PubMed  CAS  Google Scholar 

  45. Wood D, Reimherr J, Wender PH. Effects of levodopa on attention deficit disorder, residual type. Psychiatry Res 1982; 6: 13–20

    Article  PubMed  CAS  Google Scholar 

  46. Wood DR, Reimherr FW, Wender PH. The treatment of attention deficit disorder with d,l-phenylalanine. Psychiatry Res 1985; 16: 21–6

    Article  PubMed  CAS  Google Scholar 

  47. Trott GE, Friese HJ, Menzel M, et al. Use of moclobemide in children with attention deficit hyperctivity disorder [in German]. Z Kinder Jugendpsychiat 1991; 19: 248–53

    CAS  Google Scholar 

  48. Ratey J, Greenberg M, Lindem K. Combination of treatments for attention deficit disorders in adults. J Nerv Ment Dis 1991; 176: 699–701

    Google Scholar 

  49. Pomerleau O, Downey K, Stelson F, et al. Cigarette smoking in adult patients diagnosed with ADHD. J Subst Abuse 1996; 7: 373–8

    Article  Google Scholar 

  50. Conners C, Levin ED, Sparrow E, et al. Nicotine and attention in adult attention deficit hyperactivity disorder. Psychopharmacol Bull 1996; 32: 67–73

    PubMed  CAS  Google Scholar 

  51. Rapport MD, Carlson GA, Kelly KL, et al. Methylphenidate and desipramine in hospitalized children. I. Separate and combined effects on cognitive function. J Am Acad Child Adolesc Psychiatry 1993; 32: 333–42

    Article  PubMed  CAS  Google Scholar 

  52. Gammon GD, Brown TE. Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder. J Child Adolesc Psychopharmacol 1993; 3: 1–10

    Article  PubMed  CAS  Google Scholar 

  53. Aranow RB, Hudson JL, Pope HG, et al. Elevated antidepressant plasma levels after addition of fluoxetine. Am J Psychiatry 1989; 146: 911–3

    PubMed  CAS  Google Scholar 

  54. Wilens T, McDermott S, Biederman J, et al. Combined cognitive therapy and pharmacotherapy for adults with attention deficit hyperactivity disorder: a systematic chart review of 26 cases. J Cognit Psychother. In press

  55. Zametkin AJ, Rapoport JL. Neurobiology of attention deficit disorder with hyperactivity: where have we come in 50 years? J Am Acad Child Adolesc Psychiatry 1987; 26: 676–86

    Article  PubMed  CAS  Google Scholar 

  56. Elia J, Borcherding BG, Potter WZ, et al. Stimulant drug treatment of hyperactivity: biochemical correlates. Clin Pharmacol Ther 1990; 48: 57–66

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pediatric Psychopharmacology Unit, Massachusetts General Hospital and Harvard Medical School, A.C.C. 725, Boston, Massachusetts, 02114, USA

    Timothy E. Wilens, Joseph Biederman & Thomas J. Spencer

Authors
  1. Timothy E. Wilens
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joseph Biederman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thomas J. Spencer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wilens, T.E., Biederman, J. & Spencer, T.J. Pharmacotherapy of Attention Deficit Hyperactivity Disorder in Adults. Mol Diag Ther 9, 347–356 (1998). https://doi.org/10.2165/00023210-199809050-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-199809050-00002

Keywords

Search

Navigation